{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:14:44Z","timestamp":1788912884563,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007489","name":"Bausch and Lomb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40123-026-01310-7","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T15:34:19Z","timestamp":1771083259000},"page":"967-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Global Perspectives on Therapy for Noninfectious Conjunctival Hyperemia: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Melissa","family":"Toyos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Alio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Kam Lung","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Pek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Sinjab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hosny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M.","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giannaccare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"5","key":"1310_CR1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.pedhc.2016.02.001","volume":"30","author":"C Beal","year":"2016","unstructured":"Beal C, Giordano B. Clinical evaluation of red eyes in pediatric patients. J Pediatr Health Care. 2016;30(5):506\u201314.","journal-title":"J Pediatr Health Care"},{"issue":"17","key":"1310_CR2","first-page":"302","volume":"114","author":"A Frings","year":"2017","unstructured":"Frings A, Geerling G, Schargus M. Red eye: a guide for non-specialists. Dtsch Arztebl Int. 2017;114(17):302\u201312.","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"1310_CR3","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1177\/11206721211024827","volume":"31","author":"S Bonini","year":"2021","unstructured":"Bonini S. The red eye. Eur J Ophthalmol. 2021;31(6):2843\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"1310_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jtos.2021.05.003","volume":"21","author":"RB Singh","year":"2021","unstructured":"Singh RB, Liu L, Anchouche S, et al. Ocular redness - i: etiology, pathogenesis, and assessment of conjunctival hyperemia. Ocul Surf. 2021;21:134\u201344.","journal-title":"Ocul Surf"},{"key":"1310_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1091128","volume":"10","author":"J Chen","year":"2023","unstructured":"Chen J, Chen CM, Zheng Y, Zhong L. Characteristics of eye-related emergency visits and triage differences by nurses and ophthalmologists: perspective from a single eye center in southern China. Front Med-Lausanne. 2023;10:1091128.","journal-title":"Front Med-Lausanne"},{"issue":"741","key":"1310_CR6","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.3399\/BJGP.2022.0616","volume":"74","author":"A Rawlings","year":"2024","unstructured":"Rawlings A, Hobby AE, Ryan B, et al. The burden of acute eye conditions on different healthcare providers: a retrospective population-based study. Br J Gen Pract. 2024;74(741):e264\u201374.","journal-title":"Br J Gen Pract"},{"key":"1310_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2023.04.004","volume":"28","author":"JS Wolffsohn","year":"2023","unstructured":"Wolffsohn JS, Lingham G, Downie LE, et al. TFOS Lifestyle: impact of the digital environment on the ocular surface. Ocul Surf. 2023;28:213\u201352.","journal-title":"Ocul Surf"},{"issue":"4","key":"1310_CR8","doi-asserted-by":"publisher","first-page":"P134","DOI":"10.1016\/j.ophtha.2023.12.037","volume":"131","author":"AY Cheung","year":"2024","unstructured":"Cheung AY, Choi DS, Ahmad S, et al. Conjunctivitis Preferred Practice Pattern\u00ae. Ophthalmology. 2024;131(4):P134\u2013204.","journal-title":"Ophthalmology"},{"key":"1310_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/OPTO.S259398","volume":"12","author":"LO Hosten","year":"2020","unstructured":"Hosten LO, Snyder C. Over-the-counter ocular decongestants in the United States\u2014mechanisms of action and clinical utility for management of ocular redness. Clin Optom (Auckl). 2020;12:95\u2013105.","journal-title":"Clin Optom (Auckl)"},{"key":"1310_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1439-0310.2011.01888.x","volume":"117","author":"RR Provine","year":"2011","unstructured":"Provine RR, Caberera MO, Brocato NW, Krosnowski KA. When the whites of the eyes are red: a uniquely human cue. Ethology. 2011;117:395\u20139.","journal-title":"Ethology"},{"issue":"6","key":"1310_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/ICU.0b013e3283654db2","volume":"24","author":"J Peragallo","year":"2013","unstructured":"Peragallo J, Biousse V, Newman NJ. Ocular manifestations of drug and alcohol abuse. Curr Opin Ophthalmol. 2013;24(6):566\u201373.","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"1310_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.18502\/jovr.v16i2.9089","volume":"16","author":"S Karimi","year":"2021","unstructured":"Karimi S, Arabi A, Shahraki T. Alcohol and the eye. J Ophthalmic Vis Res. 2021;16(2):260\u201370.","journal-title":"J Ophthalmic Vis Res"},{"key":"1310_CR13","doi-asserted-by":"crossref","unstructured":"Lansingh VC, Eckert KA, Ramos SV, Lopez Star EM. From acute disease to red flags: a review of the diverse spectrum of red eye encountered in the primary care setting. Primary Health Care Open Access. 2018;8(4).","DOI":"10.4172\/2167-1079.1000316"},{"issue":"4","key":"1310_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/ACI.0000000000000669","volume":"20","author":"N Kimchi","year":"2020","unstructured":"Kimchi N, Bielory L. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. Curr Opin Allergy Clin Immunol. 2020;20(4):414\u201320.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1310_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jtos.2021.05.004","volume":"21","author":"RB Singh","year":"2021","unstructured":"Singh RB, Liu L, Yung A, et al. Ocular redness - II: progress in development of therapeutics for the management of conjunctival hyperemia. Ocul Surf. 2021;21:66\u201377.","journal-title":"Ocul Surf"},{"issue":"6","key":"1310_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/02713683.2022.2039205","volume":"47","author":"M Rolando","year":"2022","unstructured":"Rolando M, Merayo-Lloves J. Management strategies for evaporative dry eye disease and future perspective. Curr Eye Res. 2022;47(6):813\u201323.","journal-title":"Curr Eye Res"},{"issue":"4","key":"1310_CR17","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2023.12.041","volume":"131","author":"G Amescua","year":"2024","unstructured":"Amescua G, Ahmad S, Cheung AY, et al. Dry eye syndrome Preferred Practice Pattern\u00ae. Ophthalmology. 2024;131(4):P1\u201349.","journal-title":"Ophthalmology"},{"issue":"23","key":"1310_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239271","volume":"21","author":"K Tsubota","year":"2020","unstructured":"Tsubota K, Pflugfelder SC, Liu Z, et al. Defining dry eye from a clinical perspective. Int J Mol Sci. 2020;21(23):9271.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1310_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0039-6257(88)90071-9","volume":"33","author":"PA Jaros","year":"1988","unstructured":"Jaros PA, DeLuise VP. Pingueculae and pterygia. Surv Ophthalmol. 1988;33(1):41\u20139.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"1310_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0002-9394(98)00327-4","volume":"127","author":"J Frucht-Pery","year":"1999","unstructured":"Frucht-Pery J, Siganos CS, Solomon A, Shvartzenberg T, Richard C, Trinquand C. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol. 1999;127(2):148\u201352.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1310_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/1203475420929920","volume":"24","author":"CE Jo","year":"2020","unstructured":"Jo CE, Georgakopoulos JR, Drucker AM, Piguet V, Yeung J. Incidence of conjunctivitis and other ocular surface disorders in patients with long-term dupilumab use. J Cutan Med Surg. 2020;24(5):527\u20138.","journal-title":"J Cutan Med Surg"},{"key":"1310_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jtos.2021.02.004","volume":"20","author":"RB Park","year":"2021","unstructured":"Park RB, Jain S, Han H, Park J. Ocular surface disease associated with immune checkpoint inhibitor therapy. Ocul Surf. 2021;20:115\u201329.","journal-title":"Ocul Surf"},{"key":"1310_CR23","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.2147\/OPTH.S430861","volume":"17","author":"CM Riguetto","year":"2023","unstructured":"Riguetto CM, Barbosa EB, Atihe CC, Reis F, Alves M, Zantut-Wittmann DE. Ocular surface disease related to the inflammatory and non-inflammatory phases of thyroid eye disease. Clin Ophthalmol. 2023;17:3465\u201375.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1310_CR24","first-page":"81","volume":"67","author":"ML Macovei","year":"2023","unstructured":"Macovei ML, Neacsu AM. Diagnostic and therapeutic challenges in non-specific orbital inflammation\u2014a case report. Rom J Ophthalmol. 2023;67(1):81\u20136.","journal-title":"Rom J Ophthalmol"},{"issue":"3","key":"1310_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334\u201365.","journal-title":"Ocul Surf"},{"issue":"6","key":"1310_CR26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/opo.12888","volume":"41","author":"EB Papas","year":"2021","unstructured":"Papas EB. The global prevalence of dry eye disease: a Bayesian view. Ophthalmic Physiol Opt. 2021;41(6):1254\u201366.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"3","key":"1310_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276\u201383.","journal-title":"Ocul Surf"},{"key":"1310_CR28","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jtos.2023.08.009","volume":"30","author":"JP Craig","year":"2023","unstructured":"Craig JP, Alves M, Wolffsohn JS, et al. TFOS Lifestyle Report executive summary: a lifestyle epidemic\u2014ocular surface disease. Ocul Surf. 2023;30:240\u201353.","journal-title":"Ocul Surf"},{"issue":"1","key":"1310_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","volume":"130","author":"W Stevenson","year":"2012","unstructured":"Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90\u2013100.","journal-title":"Arch Ophthalmol"},{"key":"1310_CR30","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.2147\/OPTH.S480223","volume":"18","author":"P Munoz-Villegas","year":"2024","unstructured":"Munoz-Villegas P, Garcia-Sanchez G, Jauregui-Franco RO, Quirarte-Justo S, Sanchez-Rios A, Olvera-Montano O. Influence of environmental factors with clinical signs and symptoms in the management of dry eye disease. Clin Ophthalmol. 2024;18:2439\u201351.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"1310_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2500\/aap.2014.35.3750","volume":"35","author":"L Bielory","year":"2014","unstructured":"Bielory L, Skoner DP, Blaiss MS, et al. Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Allergy Asthma Proc. 2014;35(3):211\u20138.","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"1310_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jtos.2019.10.010","volume":"18","author":"HS Ong","year":"2020","unstructured":"Ong HS, Minassian D, Rauz S, Mehta JS, Dart JK. Validation of a clinical assessment tool for cicatrising conjunctivitis. Ocul Surf. 2020;18(1):121\u20139.","journal-title":"Ocul Surf"},{"issue":"2","key":"1310_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.anai.2019.11.014","volume":"124","author":"L Bielory","year":"2020","unstructured":"Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol. 2020;124(2):118\u201334.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1310_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjo.86.4.418","volume":"86","author":"PJ Pisella","year":"2002","unstructured":"Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418\u201323.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1310_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/bjo.2007.135111","volume":"93","author":"F Honrubia","year":"2009","unstructured":"Honrubia F, Garcia-Sanchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93(3):316\u201321.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1310_CR36","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","volume":"106","author":"C Baudouin","year":"1999","unstructured":"Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106(3):556\u201363.","journal-title":"Ophthalmology"},{"issue":"1","key":"1310_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/archopht.1997.01100150036004","volume":"115","author":"CN Soparkar","year":"1997","unstructured":"Soparkar CN, Wilhelmus KR, Koch DD, Wallace GW, Jones DB. Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. Arch Ophthalmol. 1997;115(1):34\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1310_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1442-9071.2000.00237.x","volume":"28","author":"MK Arici","year":"2000","unstructured":"Arici MK, Arici DS, Topalkara A, G\u00fcler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol. 2000;28(2):113\u20137.","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"1310_CR39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/01.all.0000183112.86181.9e","volume":"5","author":"C Baudouin","year":"2005","unstructured":"Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5(5):459\u201363.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"7","key":"1310_CR40","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1167\/iovs.04-1331","volume":"46","author":"JM Guenoun","year":"2005","unstructured":"Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46(7):2444\u201350.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"1310_CR41","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1167\/iovs.07-0266","volume":"48","author":"C Baudouin","year":"2007","unstructured":"Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48(9):4123\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1310_CR42","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jtos.2023.04.011","volume":"29","author":"JAP Gomes","year":"2023","unstructured":"Gomes JAP, Azar DT, Baudouin C, et al. TFOS lifestyle: impact of elective medications and procedures on the ocular surface. Ocul Surf. 2023;29:331\u201385.","journal-title":"Ocul Surf"},{"issue":"Suppl 2","key":"1310_CR43","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/ICL.0000000000000481","volume":"44","author":"CHL Lim","year":"2018","unstructured":"Lim CHL, Stapleton F, Mehta JS. Review of contact lens-related complications. Eye Contact Lens. 2018;44(Suppl 2):S1\u201310.","journal-title":"Eye Contact Lens"},{"issue":"2","key":"1310_CR44","volume":"16","author":"O Albasheer","year":"2024","unstructured":"Albasheer O, Gosadi IM, Abuallut I, et al. Awareness and hygiene practices among contact lens wearers: a population-based cross-sectional survey. Cureus. 2024;16(2):e54723.","journal-title":"Cureus"},{"issue":"5","key":"1310_CR45","volume":"15","author":"HA Gadain Hassan","year":"2023","unstructured":"Gadain Hassan HA. Computer vision syndrome among medical students at the University of Khartoum, Sudan: prevalence and associated factors. Cureus. 2023;15(5):e38762.","journal-title":"Cureus"},{"key":"1310_CR46","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/RMHP.S388331","volume":"15","author":"A Uwimana","year":"2022","unstructured":"Uwimana A, Ma C, Ma X. Concurrent rising of dry eye and eye strain symptoms among university students during the COVID-19 pandemic era: a cross-sectional study. Risk Manag Healthc Policy. 2022;15:2311\u201322.","journal-title":"Risk Manag Healthc Policy"},{"issue":"4","key":"1310_CR47","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.clindermatol.2023.08.009","volume":"41","author":"S Vassileva","year":"2023","unstructured":"Vassileva S, Tanev I, Drenovska K. Rosacea: the eyes have it. Clin Dermatol. 2023;41(4):528\u201336.","journal-title":"Clin Dermatol"},{"issue":"8","key":"1310_CR48","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1161\/STROKEAHA.116.013428","volume":"47","author":"LN Gonzalez Castro","year":"2016","unstructured":"Gonzalez Castro LN, Colorado RA, Botelho AA, Freitag SK, Rabinov JD, Silverman SB. Carotid-cavernous fistula: a rare but treatable cause of rapidly progressive vision loss. Stroke. 2016;47(8):e207\u20139.","journal-title":"Stroke"},{"issue":"12","key":"1310_CR49","volume":"15","author":"A Hayre","year":"2023","unstructured":"Hayre A. A quality improvement project of acute red eye consultations in primary care: improving the identification of red flags. Cureus. 2023;15(12):e50344.","journal-title":"Cureus"},{"issue":"7","key":"1310_CR50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/01.JAA.0000832600.20016.d9","volume":"35","author":"TM McSwigan","year":"2022","unstructured":"McSwigan TM, Beck D, Farkas D. A rapid review of the red eye. JAAPA. 2022;35(7):40\u20135.","journal-title":"JAAPA"},{"issue":"11","key":"1310_CR51","doi-asserted-by":"publisher","first-page":"847","DOI":"10.31128\/AJGP-09-23-6960","volume":"53","author":"C Gin","year":"2024","unstructured":"Gin C, Crock C, Wells K. Conjunctivitis: a review. Aust J Gen Pract. 2024;53(11):847\u201352.","journal-title":"Aust J Gen Pract"},{"issue":"Suppl 1","key":"1310_CR52","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0039-6257(96)82027-3","volume":"41","author":"J Burke","year":"1996","unstructured":"Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(Suppl 1):S9\u201318.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"1310_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cxo.12846","volume":"102","author":"SL Ackerman","year":"2019","unstructured":"Ackerman SL, Torkildsen GL, McLaurin E, Vittitow JL. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials. Clin Exp Optom. 2019;102(2):131\u20139.","journal-title":"Clin Exp Optom"},{"key":"1310_CR54","unstructured":"DiVito M, Evans DG, Vollmer PM, McGee S. Evaluation of the safety of a novel preservative-free formulation of brimonidine tartrate ophthalmic solution. The Association for Research in Vision and Ophthalmology; May 5\u20139; Seattle, 2024."},{"key":"1310_CR55","unstructured":"Vollmer PM, DiVito M, Evans DG, Wesley G. Evaluation of the efficacy of a novel preservative-free formulation of brimonidine tartrate ophthalmic solution. The Association for Research in Vision and Ophthalmology; May 5\u20139; Seattle, 2024."},{"issue":"6","key":"1310_CR56","volume":"2015","author":"M Castillo","year":"2015","unstructured":"Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015;2015(6):CD009566.","journal-title":"Cochrane Database Syst Rev"},{"key":"1310_CR57","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/OPTO.S412382","volume":"16","author":"AD Pucker","year":"2024","unstructured":"Pucker AD, Kerr AM, Sanderson J, Lievens C. Digital eye strain: updated perspectives. Clin Optom (Auckl). 2024;16:233\u201346.","journal-title":"Clin Optom (Auckl)"},{"issue":"4","key":"1310_CR58","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jtos.2020.05.006","volume":"18","author":"S Erickson","year":"2020","unstructured":"Erickson S, Sullivan AG, Barabino S, et al. TFOS European Ambassador meeting: unmet needs and future scientific and clinical solutions for ocular surface diseases. Ocul Surf. 2020;18(4):936\u201362.","journal-title":"Ocul Surf"},{"key":"1310_CR59","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jtos.2021.08.014","volume":"22","author":"S Erickson","year":"2021","unstructured":"Erickson S, Sullivan AG, Abad JC, et al. TFOS: unique challenges and unmet needs for the management of ocular surface diseases throughout the world. Ocul Surf. 2021;22:242\u20134.","journal-title":"Ocul Surf"},{"issue":"5","key":"1310_CR60","volume":"16","author":"MW Bin Maneea","year":"2024","unstructured":"Bin Maneea MW, Alamawi HO, Almuqbil A, et al. Digital eye straining: exploring its prevalence, associated factors, and effects on the quality of life. Cureus. 2024;16(5):e59442.","journal-title":"Cureus"},{"key":"1310_CR61","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jtos.2023.04.010","volume":"29","author":"L Jones","year":"2023","unstructured":"Jones L, Efron N, Bandamwar K, et al. TFOS Lifestyle: impact of contact lenses on the ocular surface. Ocul Surf. 2023;29:175\u2013219.","journal-title":"Ocul Surf"},{"issue":"1","key":"1310_CR62","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2013.08.007","volume":"121","author":"PS Bilkhu","year":"2014","unstructured":"Bilkhu PS, Wolffsohn JS, Naroo SA, Robertson L, Kennedy R. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. Ophthalmology. 2014;121(1):72\u20138.","journal-title":"Ophthalmology"},{"issue":"4","key":"1310_CR63","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1080\/09273948.2018.1432764","volume":"27","author":"H Nakatani","year":"2019","unstructured":"Nakatani H, Gomes P, Bradford R, Guo Q, Safyan E, Hollander DA. Alcaftadine 0.25% versus olopatadine 0.1% in preventing cedar pollen allergic conjunctivitis in Japan: a randomized study. Ocul Immunol Inflamm. 2019;27(4):622-631.","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"1310_CR64","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1034\/j.1600-0420.2003.00079.x","volume":"81","author":"V Yaylali","year":"2003","unstructured":"Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand. 2003;81(4):378\u201382.","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"1310_CR65","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/ACI.0000000000000473","volume":"18","author":"H Ben-Eli","year":"2018","unstructured":"Ben-Eli H, Solomon A. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends. Curr Opin Allergy Clin Immunol. 2018;18(5):411\u20136.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"9","key":"1310_CR66","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s40123-025-01194-z","volume":"14","author":"M Toyos","year":"2025","unstructured":"Toyos M, DiVito M, Messmer EM, et al. A multicenter randomized double-masked study comparing preservative-free brimonidine tartrate ophthalmic solution 0.025% with LUMIFY\u00ae 0.025% for ocular redness in adults. Ophthalmol Therapy. 2025;14(9):2283\u201399.","journal-title":"Ophthalmol Therapy"},{"issue":"8","key":"1310_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183461","volume":"12","author":"N Gupta","year":"2017","unstructured":"Gupta N, Vashist P, Tandon R, Gupta SK, Kalaivani M, Dwivedi SN. Use of traditional eye medicine and self-medication in rural India: a population-based study. PLoS ONE. 2017;12(8):e0183461.","journal-title":"PLoS ONE"},{"issue":"11","key":"1310_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063147","volume":"12","author":"H Tesfay","year":"2022","unstructured":"Tesfay H, Fiseha K, Abera S, Mihreteab Siele S, Tesfamariam EH, Abdu N. Self-medication with ophthalmic drugs and its associated factors among ophthalmic patients attending three hospitals in Asmara, Eritrea: a cross-sectional study. BMJ Open. 2022;12(11):e063147.","journal-title":"BMJ Open"},{"issue":"8","key":"1310_CR69","volume":"15","author":"SS Alamer","year":"2023","unstructured":"Alamer SS, Alazzam SM, Alanazi AK, et al. Ophthalmic self-medication practices and associated factors of using steroid eye drops among adult ophthalmic patients. Cureus. 2023;15(8):e43110.","journal-title":"Cureus"},{"key":"1310_CR70","unstructured":"US Food & Drug Administration. FDA warns consumers not to purchase or use certain eye drops from several major brands due to risk of eye infection. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-consumers-not-purchase-or-use-certain-eye-drops-several-major-brands-due-risk-eye. Accessed January 28, 2026."},{"key":"1310_CR71","unstructured":"US Food & Drug Administration. FDA warns consumers of contaminated copycat eye drops. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-consumers-contaminated-copycat-eye-drops. Accessed January 28, 2026."},{"issue":"4","key":"1310_CR72","first-page":"415","volume":"85","author":"C Soares Ronconi","year":"2021","unstructured":"Soares Ronconi C, Issaho DC, Ejzenbaum F, et al. Brazilian guidelines for the monitoring and treatment of pediatric allergic conjunctivitis. Arq Bras Oftalmol. 2021;85(4):415\u201325.","journal-title":"Arq Bras Oftalmol"},{"issue":"1","key":"1310_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13010-024-00151-1","volume":"19","author":"EB da Prato","year":"2024","unstructured":"da Prato EB, Cartier H, Margara A, et al. The ethical foundations of patient-centered care in aesthetic medicine. Philos Ethics Humanit Med. 2024;19(1):1.","journal-title":"Philos Ethics Humanit Med"},{"key":"1310_CR74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jtos.2023.04.005","volume":"29","author":"DA Sullivan","year":"2023","unstructured":"Sullivan DA, da Costa AX, Del Duca E, et al. TFOS Lifestyle: impact of cosmetics on the ocular surface. Ocul Surf. 2023;29:77\u2013130.","journal-title":"Ocul Surf"},{"issue":"3","key":"1310_CR75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2307\/3527467","volume":"1","author":"D Callahan","year":"1973","unstructured":"Callahan D. The WHO definition of \u201chealth.\u201d Hastings Cent Stud. 1973;1(3):77\u201387.","journal-title":"Hastings Cent Stud"},{"key":"1310_CR76","unstructured":"Boyd K. Redness-relieving eye drops. https:\/\/www.aao.org\/eye-health\/treatments\/redness-relieving-eye-drops. Accessed January 28, 2026."},{"key":"1310_CR77","unstructured":"U.S. Food and Drug Administration. Over-the-Counter (OTC) Monograph M018: ophthalmic drug products for over-the-counter human use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/omuf\/monographs\/OTC%20Monograph_M018-Ophthalmic%20Drug%20Products%20for%20OTC%20Human%20Use%2004.04.22.pdf. Accessed January 28, 2026."},{"issue":"4","key":"1310_CR78","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000093076","volume":"220","author":"I Petricek","year":"2006","unstructured":"Petricek I, Prost M, Popova A. The differential diagnosis of red eye: a survey of medical practitioners from Eastern Europe and the Middle East. Ophthalmologica. 2006;220(4):229\u201337.","journal-title":"Ophthalmologica"},{"issue":"2","key":"1310_CR79","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/0976-9668.160009","volume":"6","author":"A Farokhfar","year":"2015","unstructured":"Farokhfar A, Dailami KN, Heidari Gorji MA, Aghaie N. Epidemiology and symptoms of red eyes in patients from Northern Iran. J Nat Sci Biol Med. 2015;6(2):369\u201371.","journal-title":"J Nat Sci Biol Med"},{"issue":"6","key":"1310_CR80","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/cea.12536","volume":"45","author":"A Leonardi","year":"2015","unstructured":"Leonardi A, Piliego F, Castegnaro A, et al. Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy. 2015;45(6):1118\u201325.","journal-title":"Clin Exp Allergy"},{"issue":"1 Suppl 1","key":"1310_CR81","first-page":"49","volume":"32","author":"M Sacchetti","year":"2018","unstructured":"Sacchetti M, Abicca I, Bruscolini A, Cavaliere C, Nebbioso M, Lambiase A. Allergic conjunctivitis: current concepts on pathogenesis and management. J Biol Regul Homeost Agents. 2018;32(1 Suppl 1):49\u201360.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"1","key":"1310_CR82","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/ojo.ojo_17_23","volume":"17","author":"M Arunachalam","year":"2024","unstructured":"Arunachalam M, Devadas BS, Saravanakumar P, Premnath G, Bravian SP. Knowledge, attitude, and practice about red eye among the general population visiting a tertiary care hospital in rural setting, Tamil Nadu, India. Oman J Ophthalmol. 2024;17(1):78\u201383.","journal-title":"Oman J Ophthalmol"},{"issue":"1","key":"1310_CR83","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/2249-4863.184630","volume":"5","author":"OT Bodunde","year":"2016","unstructured":"Bodunde OT, Sholeye OO, Onabolu OO, Otulana TO, Ajibode HA. Perception of red eye among senior secondary students in Sagamu, Southwest Nigeria. J Family Med Prim Care. 2016;5(1):89\u201393.","journal-title":"J Family Med Prim Care"},{"issue":"3","key":"1310_CR84","first-page":"E24","volume":"100","author":"AQ Tran","year":"2017","unstructured":"Tran AQ, Hoeppner C, Venkateswaran N, Choi DS, Lee WW. Complications of cosmetic eye whitening. Cutis. 2017;100(3):E24\u20136.","journal-title":"Cutis"},{"key":"1310_CR85","first-page":"445","volume":"9","author":"M Moshirfar","year":"2015","unstructured":"Moshirfar M, McCaughey MV, Fenzl CR, Santiago-Caban L, Kramer GD, Mamalis N. Delayed manifestation of bilateral scleral thinning after I-BRITE\u00ae procedure and review of literature for cosmetic eye-whitening procedures. Clin Ophthalmol. 2015;9:445\u201351.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"1310_CR86","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/ICO.0b013e318211467d","volume":"31","author":"BH Kim","year":"2012","unstructured":"Kim BH. Regional conjunctivectomy with postoperative mitomycin C to treat chronic hyperemic conjunctiva. Cornea. 2012;31(3):236\u201344.","journal-title":"Cornea"},{"issue":"3","key":"1310_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/1869-5760-3-39","volume":"22","author":"TG Leung","year":"2013","unstructured":"Leung TG, Dunn JP, Akpek EK, Thorne JE. Necrotizing scleritis as a complication of cosmetic eye whitening procedure. J Ophthalmic Inflamm Infect. 2013;22(3):39.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"3","key":"1310_CR88","first-page":"77","volume":"29","author":"NS Azar","year":"2023","unstructured":"Azar NS, Ruiz-Lozano RE, Quiroga-Garza ME, et al. Delayed presentation of surgically induced scleral necrosis after I-BRITE procedure treated with immunosuppressive therapy. Digit J Ophthalmol. 2023;29(3):77\u201382.","journal-title":"Digit J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01310-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01310-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:27:59Z","timestamp":1773156479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01310-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01310-7","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Melissa Toyos reports serving as a consultant to Bausch\u2009+\u2009Lomb, Eyevance, Iridex, Mallinckrodt, Shire, Sun Pharmaceutical Industries, Inc., and Zeiss; serving on the speakers\u2019 bureau for Bausch\u2009+\u2009Lomb, Iridex, Lumenis, Mallinckrodt, Shire, Sun Pharmaceutical Industries, Inc., and Zeiss; receiving research support from Bausch\u2009+\u2009Lomb, DigiSight, Domp\u00e9 farmaceutici, Iridex, Kala Pharmaceuticals, Lumenis, Magellan, Mallinckrodt, MIXTO Lasering, Ocular Technologies, Oculus, Opternative, RevitaLid, Shire, Sun Pharmaceutical Industries, and Zeiss; and receiving miscellaneous fees from MIXTO Lasering. Clara C. Chan reports serving on advisory boards, speakers bureaus, or as a consultant for AbbVie, Aurion Biotech, Bausch\u2009+\u2009Lomb, Johnson & Johnson, Kala Ophthalmics, Labtician Ophthalmics, Novartis, Santen Pharmaceutical, Sun Pharmaceutical Industries, Th\u00e9a Pharma, and Valeo Pharma; and receiving research funding from Aurion Biotech, Claris Bio, and CorNeat. Jorge L. Alio is an Editorial Board member of\n                      Ophthalmology and Therapy\n                      . Jorge L. Alio was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kelvin Kam Lung Chong reports nothing to disclose. Don Pek reports serving as a consultant and advisor to Allergan, Bausch\u2009+\u2009Lomb, and Johnson & Johnson Vision. Serge Doan reports serving as a consultant to Alcon, Bausch\u2009+\u2009Lomb, Horus, Santen, and Th\u00e9a Pharma. Mazen Sinjab reports nothing to disclose. Mohamed Hosny reports being a consultant to Alcon, Bausch\u2009+\u2009Lomb, Biotech Healthcare, BVI, iVis Technologies, Mediworks, and Ziemer Ophthalmic Systems. Elisabeth M. Messmer reports serving as a consultant to Alfa Intes Industria Terapeutica Splendore, DMG, Kala Ophthalmics, Sanofi, Shire, Sun Pharmaceutical Industries, SIFI, and Viatris; serving as a speaker for Bausch\u2009+\u2009Lomb and GSK; serving as a consultant and speaker for Alcon\/Novartis, Domp\u00e9 farmaceutici, Novaliq, Santen, Th\u00e9a Pharma, TRB-Chemedica, and VISUfarma; and receiving research funding from Recordati Rare Diseases. Giuseppe Giannaccare reports serving on advisory boards, speakers bureaus, or as a consultant for Espansione Group, Off Health, Santen Pharmaceutical, Bausch\u2009+\u2009Lomb, Th\u00e9a Pharma, FB Vision, Fidia, Alcon, Bruschettini, Alfa Intes, SIFI, DOC, and VISUfarma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}